This assay was performed by exposing tumor cell suspensions (treated with 50 μM of CA-IX inhibitors, a subtoxic concentration) toward gradients of serum obtained by putting medium with 1 and 5% FBS in the lower compartments. Here, CA9 is linked to neoplasm.